BiotechTube

decitabine + azacitidine

ApprovedTerminated
0 watching 0 views this week🔥 Hot
85
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Myelodysplastic Syndromes

Conditions

Myelodysplastic Syndromes

Trial Timeline

Nov 1, 2009 → —

NCT ID
NCT01011283

About decitabine + azacitidine

decitabine + azacitidine is a approved stage product being developed by Eisai for Myelodysplastic Syndromes. The current trial status is terminated. This product is registered under clinical trial identifier NCT01011283. Target conditions include Myelodysplastic Syndromes.

Hype Score Breakdown

Clinical
30
Activity
20
Company
10
Novelty
10
Community
12

Clinical Trials (1)

NCT IDPhaseStatus
NCT01011283ApprovedTerminated

Competing Products

20 competing products in Myelodysplastic Syndromes

See all competitors
ProductCompanyStageHype Score
NEX-18a injection + Azacitidine InjectionNanexa ABPhase 1
28
JSP191Jasper TherapeuticsPhase 1
25
Humanized anti-CD117 Monoclonal Antibody (JSP191)Jasper TherapeuticsPhase 1
25
GTB-3550 TriKE® Phase I + GTB-3550 TriKE® Phase IIGT BiopharmaPhase 1/2
33
Erlotinib HydrochlorideAstellas PharmaPhase 2
52
Decitabine + Decitabine + DecitabineEisaiPhase 2
52
Decitabine + Valproic AcidEisaiPhase 2
52
decitabine + decitabineEisaiPhase 2
52
DecitabineEisaiPhase 2
52
decitabine + decitabine + decitabine + decitabineEisaiPhase 1
33
Decitabine, Arsenic Trioxide and Ascorbic AcidEisaiPhase 2
52
Subcutaneous DecitabineEisaiPhase 1
33
DecitabineEisaiPhase 2
52
Galunisertib + PlaceboEli LillyPhase 2/3
65
DSP-7888Sumitomo PharmaPhase 1/2
41
TP-0184Sumitomo PharmaPhase 1/2
41
DecitabineJohnson & JohnsonPhase 2
52
Epoetin alfaJohnson & JohnsonPhase 2
52
ZARNESTRA, tipifarnib, R115777Johnson & JohnsonPhase 2
52
DecitabineJohnson & JohnsonPhase 2
52

Other Products from Eisai

MecobalaminApproved
85
MonteplaseApproved
85
E2020 + PlaceboApproved
85
Palonosetron 0.075 mg IV + Dexamethasone 10 mg IV + Promethazine 25 mg IVApproved
85
DonepezilApproved
85